Literature DB >> 22908167

Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Molly E Steed1, Brian J Werth, Cortney E Ireland, Michael J Rybak.   

Abstract

Daptomycin-nonsusceptible (DNS) Staphylococcus aureus is found in difficult-to-treat infections, and the optimal therapy is unknown. We investigated the activity of high-dose (HD) daptomycin plus trimethoprim-sulfamethoxazole de-escalated to HD daptomycin or trimethoprim-sulfamethoxazole against 4 clinical DNS methicillin-resistant S. aureus (MRSA) isolates in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations (10(9) CFU/g). Simulated regimens included HD daptomycin at 10 mg/kg/day for 14 days, trimethoprim-sulfamethoxazole at 160/800 mg every 12 h for 14 days, HD daptomycin plus trimethoprim-sulfamethoxazole for 14 days, and the combination for 7 days de-escalated to HD daptomycin for 7 days and de-escalated to trimethoprim-sulfamethoxazole for 7 days. Differences in CFU/g (at 168 and 336 h) were evaluated by analysis of variance (ANOVA) with a Tukey's post hoc test. Daptomycin MICs were 4 μg/ml (SA H9749-1, vancomycin-intermediate Staphylococcus aureus; R6212, heteroresistant vancomycin-intermediate Staphylococcus aureus) and 2 μg/ml (R5599 and R5563). Trimethoprim-sulfamethoxazole MICs were ≤0.06/1.19 μg/ml. HD daptomycin plus trimethoprim-sulfamethoxazole displayed rapid bactericidal activity against SA H9749-1 (at 7 h) and R6212 (at 6 h) and bactericidal activity against R5599 (at 72 h) and R5563 (at 36 h). A ≥8 log(10) CFU/g decrease was observed with HD daptomycin plus trimethoprim-sulfamethoxazole against all strains (at 48 to 144 h), which was maintained with de-escalation to HD daptomycin or trimethoprim-sulfamethoxazole at 336 h. The combination for 14 days and the combination for 7 days de-escalated to HD daptomycin or trimethoprim-sulfamethoxazole was significantly better than daptomycin monotherapy (P < 0.05) and trimethoprim-sulfamethoxazole monotherapy (P < 0.05) at 168 and 336 h. Combination therapy followed by de-escalation offers a novel bactericidal therapeutic alternative for high-inoculum, serious DNS MRSA infections.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22908167      PMCID： PMC3486589          DOI： 10.1128/AAC.01185-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  35 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

3.  An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.

Authors:  Longzhu Cui; Taisuke Isii; Minoru Fukuda; Tomonori Ochiai; Hui-Min Neoh; Ilana Lopes Baratella da Cunha Camargo; Yukiko Watanabe; Mitsutaka Shoji; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

4.  Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.

Authors:  Nagendra N Mishra; George Y Liu; Michael R Yeaman; Cynthia C Nast; Richard A Proctor; James McKinnell; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

5.  In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  Lysyl-phosphatidylglycerol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: implications for daptomycin resistance.

Authors:  Erin Kilelee; Antje Pokorny; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

7.  Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus.

Authors:  Soo-Jin Yang; Barry N Kreiswirth; George Sakoulas; Michael R Yeaman; Yan Q Xiong; Ayumi Sawa; Arnold S Bayer
Journal:  J Infect Dis       Date:  2009-12-15       Impact factor: 5.226

8.  Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

Authors:  Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2009-10       Impact factor: 2.803

9.  Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.

Authors:  Nagendra N Mishra; Soo-Jin Yang; Ayumi Sawa; Aileen Rubio; Cynthia C Nast; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

10.  The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion.

Authors:  Christoph M Ernst; Petra Staubitz; Nagendra N Mishra; Soo-Jin Yang; Gabriele Hornig; Hubert Kalbacher; Arnold S Bayer; Dirk Kraus; Andreas Peschel
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823
View more
  12 in total

Review 1.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

2.  Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Authors:  B J Werth; M E Steed; C E Ireland; T T Tran; P Nonejuie; B E Murray; W E Rose; G Sakoulas; J Pogliano; C A Arias; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  High-dose daptomycin monotherapy cures Staphylococcus epidermidis 'endotipsitis' after failure of conventional therapy.

Authors:  Julia Marie Colston; Matthew Scarborough; Jane Collier; Ian C J W Bowler
Journal:  BMJ Case Rep       Date:  2013-04-16

4.  Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Authors:  Brian J Werth; Laura M Shireman
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

5.  Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Authors:  Jordan R Smith; Juwon Yim; Seth Rice; Kyle Stamper; Razie Kebriaei; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.

Authors:  Kimberly C Claeys; Jordan R Smith; Anthony M Casapao; Ryan P Mynatt; Lisa Avery; Anjali Shroff; Deborah Yamamura; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

7.  Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; George Sakoulas; Warren E Rose; Joseph Pogliano; Ryan Tewhey; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

8.  Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.

Authors:  Jordan R Smith; Anu Arya; Juwon Yim; Katie E Barber; Jessica Hallesy; Nivedita B Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

9.  High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.

Authors:  Jordan R Smith; Kimberly C Claeys; Katie E Barber; Michael J Rybak
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.725

10.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.